WEST TISBURY, Massachusetts
Radikal Therapeutics today announced that the National Institutes of Health has awarded the Company $263,034 for investigation of a novel series of small molecule therapeutics intended for treatment of autoimmune enterocolitis. The funding will allow the Company to advance its small molecule drug discovery program focused on targeting of T cell dysregulation in the setting of inflammatory bowel disease. Chairman Andrew L. Salzman, M.D. noted that the NIH funding follows from strong preclinical data revealing potent activity of R-412, the Company’s therapeutic candidate, a novel chemokine variant that activates immunotolerance via the modulation of Tr1 cell polarization. The Phase 1 SBIR funding will support its advancement in manufacturing, pharmacology, and toxicology.
About Radikal Therapeutics (RTX)
RTX is a multi-national biotechnology firm focused on the discovery and development of transformative pharmaceuticals. With a deep pipeline of therapeutics created in-house, and a paradigm-disruptive discovery engine, the Company is positioned to remain at the forefront of drug discovery. RTX’s team of chemists, biologists, immunologists, and drug development professionals has worked together for more than two decades and has built a reputation for leadership in basic science and drug development. The Company is developing best-in-class therapeutics in a range of clinical areas, including inflammation, ischemia-reperfusion injury, and auto-immunity. The product platforms include small and large molecule pharmaceuticals that therapeutically restore free radical equilibrium, redirect aberrant signaling pathways in inflammation, manipulate mitochondrial cell death pathways, modulate DNA repair, restore microcirculatory perfusion, and induce specific immunotolerance. Although varied in their structural targets and directed at diverse clinical needs, the Company’s technologies share a unified concept of correcting pathophysiology by endowing agents with multi-functional capacity. This approach yields biological synergies that far outstrip the potency of traditional single-target agents.
Via its sister firm Luria Scientific Industries (LSI), RTX makes available its deep and unique experience in pre-clinical and clinical development for the benefit of the biotech and pharmaceutical industry.
Andrew L. Salzman, M.D.